Tyrosine kinase inhibitorPhase 3 trialInvestigational
Mobocertinib
How it works
Blocks the EGFR and HER2 receptors on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR exon 20 insertion
Efficacy
In clinical trials, around 43% of EGFR exon 20 insertion patients achieved an objective response, with median progression-free survival of approximately 5.2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.